DCM
DNTH icon

Dupont Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Dupont Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,722
Closed -$122K – 1716
2021
Q4 		$122K Sell
1,722
-686
-28% -$69K ﹤0.01% 1255
2021
Q3 		$280K Buy
2,408
+768
+47% +$89.5K 0.01% 1101
2021
Q2 		$257K Buy
+1,640
New +$301K 0.01% 1247

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dupont Capital Management's DNTH Position: Q1 2022 in Review

Dupont Capital Management sold out of Dianthus Therapeutics (DNTH) in Q1 2022, closing a stake of 1,722 shares — an estimated $122K sold.

Dupont Capital Management first reported a position in DNTH in Q2 2021 and held it in 3 quarters. The position peaked at $280K in Q3 2021. 93 funds tracked by Wall St. Rank hold DNTH as of Q1 2022.

  • Dupont Capital Management reported no remaining Dianthus Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Dupont Capital Management sold 1,722 Dianthus Therapeutics shares in Q1 2022, an estimated $122K.
  • Dupont Capital Management first reported a position in Dianthus Therapeutics in Q2 2021 and held it in 3 quarters.
  • Dupont Capital Management's Dianthus Therapeutics position peaked at $280K in Q3 2021.
  • 93 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2022.

Based on Dupont Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.